Aino Forstén

Effectiveness of the 10-Valent Pneumococcal Nontypeable<i>Haemophilus influenzae</i>Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland

Timo Vesikari, Aino Forstén, Ilkka Seppä et al. · Journal of the Pediatric Infectious Diseases Society · 2016 · 81 citations · Full text

Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

Timo Vesikari, Aino Forstén, Karl–Heinz Herbinger et al. · Vaccine · 2011 · 55 citations

Vaccinology, Vaccine Safety, Cross-protection +8

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

Timo Vesikari, Aino Forstén, Dominique Boutriau et al. · Human Vaccines & Immunotherapeutics · 2012 · 44 citations · Full text

Immunodeficiencies, Immunology, Immunodominance +17

Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines

Timo Vesikari, Aino Forstén, Véronique Bianco et al. · The Pediatric Infectious Disease Journal · 2015 · 41 citations

An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccines to Healthy Adolescents 11–15 Years of Age

Pope Kosalaraksa, Jesper Mehlsen, Timo Vesikari et al. · The Pediatric Infectious Disease Journal · 2015 · 37 citations